Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06935266 · ClinicalTrials.gov registry record · Phase 1
A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT06935266 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 64 participants.
The verdict
NCT06935266, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The main aim of this study is to check how well healthy adults can tolerate TAK-881 with different dosing schedules. During the study, participants will receive one infusion of TAK-881 under the skin (subcutaneous \[SC\] infusion) on Day 1 at a lower dose level followed by participants receiving multiple infusion of higher dose levels. Participants will be in the study for approximately 19 weeks including screening period and follow-up (End of Treatment \[EOT\]).
Interventions
- BIOLOGICAL TAK-881
- DEVICE SC Investigational Needle Sets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2025-04-22 |
| Est. Completion | 2025-09-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06935266
The ClinicalTrials.gov registry entry for NCT06935266 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAK-881 is the first listed.
NCT06935266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06935266 about?
NCT06935266 is a clinical study titled "A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults". The main aim of this study is to check how well healthy adults can tolerate TAK-881 with different dosing schedules. During the study, participants will receive one infusion of TAK-881 under the skin (subcutaneous \[SC\] infusion) on Day 1 at a lower dose level followed by participants receiving mu...
What is the current status of trial NCT06935266?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2025-04-22. Estimated completion is 2025-09-22.
What interventions are being tested in trial NCT06935266?
The interventions under investigation include: TAK-881 (BIOLOGICAL), SC Investigational Needle Sets (DEVICE).
Who is sponsoring clinical trial NCT06935266?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.